Ad26.RSV.preF-based vaccine — Competitive Intelligence Brief

Ad26.RSV.preF-based vaccine (Ad26.RSV.preF-based vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Viral vector vaccine. Area: Immunology / Infectious Disease.

phase 3 Viral vector vaccine RSV prefusion F protein Immunology / Infectious Disease Biologic

Target snapshot

Ad26.RSV.preF-based vaccine (Ad26.RSV.preF-based vaccine) — Janssen Vaccines & Prevention B.V.. An adenovirus serotype 26 (Ad26)-based vaccine expressing the respiratory syncytial virus (RSV) prefusion F protein to elicit immune responses against RSV infection.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ad26.RSV.preF-based vaccine TARGET	Ad26.RSV.preF-based vaccine	Janssen Vaccines & Prevention B.V.	phase 3	Viral vector vaccine	RSV prefusion F protein
Ad26.COV2.S vaccine	Ad26.COV2.S vaccine	University Medical Center Groningen	marketed	viral vector vaccine	SARS-CoV-2 spike protein
rVSV∆G-ZEBOV-GP	rVSV∆G-ZEBOV-GP	University of Birmingham	marketed	Live attenuated viral vector vaccine	Zaire ebolavirus glycoprotein (EBOV-GP)
TT	TT	CanSino Biologics Inc.	marketed	Viral vector vaccine	SARS-CoV-2 spike protein
batch 1 of Ad5-nCoV	batch 1 of Ad5-nCoV	Jiangsu Province Centers for Disease Control and Prevention	marketed	viral vector vaccine	SARS-CoV-2 spike protein
Intramuscularly administered Ad5-nCoV vaccine	Intramuscularly administered Ad5-nCoV vaccine	Jiangsu Province Centers for Disease Control and Prevention	marketed	viral vector vaccine	SARS-CoV-2 spike protein
batch 3 of Ad5-nCoV	batch 3 of Ad5-nCoV	Jiangsu Province Centers for Disease Control and Prevention	marketed	viral vector vaccine	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Viral vector vaccine class)

1. Janssen Vaccines & Prevention B.V. · 5 drugs in this class
2. University of Oxford · 3 drugs in this class
3. Crucell Holland BV · 3 drugs in this class
4. National Institute of Allergy and Infectious Diseases (NIAID) · 2 drugs in this class
5. Bharat Biotech International Limited · 2 drugs in this class
6. Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation · 1 drug in this class
7. London School of Hygiene and Tropical Medicine · 1 drug in this class
8. Samia Hassan El-Shishtawy · 1 drug in this class
9. University Medicine Greifswald · 1 drug in this class
10. Aeras · 1 drug in this class